Cargando…
Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial whe...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nagoya University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748329/ https://www.ncbi.nlm.nih.gov/pubmed/36544593 http://dx.doi.org/10.18999/nagjms.84.4.733 |
_version_ | 1784849802040705024 |
---|---|
author | Rodríguez Meza, Miguel Ricardo Nakamura, Masanao Yamamura, Takeshi Maeda, Keiko Sawada, Tsunaki Ishikawa, Eri Kakushima, Naomi Furukawa, Kazuhiro Iida, Tadashi Mizutani, Yasuyuki Ishikawa, Takuya Ohno, Eizaburo Honda, Takashi Kawashima, Hiroki Ishigami, Masatoshi |
author_facet | Rodríguez Meza, Miguel Ricardo Nakamura, Masanao Yamamura, Takeshi Maeda, Keiko Sawada, Tsunaki Ishikawa, Eri Kakushima, Naomi Furukawa, Kazuhiro Iida, Tadashi Mizutani, Yasuyuki Ishikawa, Takuya Ohno, Eizaburo Honda, Takashi Kawashima, Hiroki Ishigami, Masatoshi |
author_sort | Rodríguez Meza, Miguel Ricardo |
collection | PubMed |
description | There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial when discussing a patient’s prognosis and important when dealing with UC management. The aim of this study was to clarify the most common comorbidities associated with UC, emphasizing immunologic comorbidities in Japan. This study was a retrospective analysis performed at Nagoya University Hospital. The data collection started in March, 2019, and continued for two years. We retrieved the medical records of 105 patients with UC diagnosis, from which the data of 176 EIMs were extracted and analyzed. Results showed that EIMs with UC in the active phase accounted for 43.7% of total EIMs. Twenty-six patients with immune-mediated inflammatory disease frequently had an active phase (odds ratio [OR] 3.84, 99% CI, 1.44–10.27). Comorbidities showing an active manifestation of symptoms and UC in the active phase were significantly correlated in patients with immunological comorbidities, such as peripheral arthritis (r = 0.97, p < 0.01) and rheumatoid arthritis (RA) (r = 0.99, p < 0.01), as well as in patients with primary sclerosis cholangitis (PSC) (r = 0.98, p < 0.01). In conclusion, this analysis suggests the importance of having full comprehension of how immunological comorbidities affect the natural development of UC, which is of vital importance to prevent further UC complications and properly adjust the management of the disease. |
format | Online Article Text |
id | pubmed-9748329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nagoya University |
record_format | MEDLINE/PubMed |
spelling | pubmed-97483292022-12-20 Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases Rodríguez Meza, Miguel Ricardo Nakamura, Masanao Yamamura, Takeshi Maeda, Keiko Sawada, Tsunaki Ishikawa, Eri Kakushima, Naomi Furukawa, Kazuhiro Iida, Tadashi Mizutani, Yasuyuki Ishikawa, Takuya Ohno, Eizaburo Honda, Takashi Kawashima, Hiroki Ishigami, Masatoshi Nagoya J Med Sci Original Paper There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial when discussing a patient’s prognosis and important when dealing with UC management. The aim of this study was to clarify the most common comorbidities associated with UC, emphasizing immunologic comorbidities in Japan. This study was a retrospective analysis performed at Nagoya University Hospital. The data collection started in March, 2019, and continued for two years. We retrieved the medical records of 105 patients with UC diagnosis, from which the data of 176 EIMs were extracted and analyzed. Results showed that EIMs with UC in the active phase accounted for 43.7% of total EIMs. Twenty-six patients with immune-mediated inflammatory disease frequently had an active phase (odds ratio [OR] 3.84, 99% CI, 1.44–10.27). Comorbidities showing an active manifestation of symptoms and UC in the active phase were significantly correlated in patients with immunological comorbidities, such as peripheral arthritis (r = 0.97, p < 0.01) and rheumatoid arthritis (RA) (r = 0.99, p < 0.01), as well as in patients with primary sclerosis cholangitis (PSC) (r = 0.98, p < 0.01). In conclusion, this analysis suggests the importance of having full comprehension of how immunological comorbidities affect the natural development of UC, which is of vital importance to prevent further UC complications and properly adjust the management of the disease. Nagoya University 2022-11 /pmc/articles/PMC9748329/ /pubmed/36544593 http://dx.doi.org/10.18999/nagjms.84.4.733 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Original Paper Rodríguez Meza, Miguel Ricardo Nakamura, Masanao Yamamura, Takeshi Maeda, Keiko Sawada, Tsunaki Ishikawa, Eri Kakushima, Naomi Furukawa, Kazuhiro Iida, Tadashi Mizutani, Yasuyuki Ishikawa, Takuya Ohno, Eizaburo Honda, Takashi Kawashima, Hiroki Ishigami, Masatoshi Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
title | Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
title_full | Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
title_fullStr | Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
title_full_unstemmed | Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
title_short | Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
title_sort | analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748329/ https://www.ncbi.nlm.nih.gov/pubmed/36544593 http://dx.doi.org/10.18999/nagjms.84.4.733 |
work_keys_str_mv | AT rodriguezmezamiguelricardo analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT nakamuramasanao analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT yamamuratakeshi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT maedakeiko analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT sawadatsunaki analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT ishikawaeri analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT kakushimanaomi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT furukawakazuhiro analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT iidatadashi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT mizutaniyasuyuki analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT ishikawatakuya analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT ohnoeizaburo analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT hondatakashi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT kawashimahiroki analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases AT ishigamimasatoshi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases |